AC Immune (ACIU) Liabilities and Shareholders Equity (2015 - 2025)

AC Immune (ACIU) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $193.0 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 26.78% year-over-year to $193.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $637.3 million (down 38.9% YoY) and the FY2025 annual result came in at $186.0 million, down 29.42% from the prior year.
• Liabilities and Shareholders Equity slipped to $193.0 million in Q4 2025 per ACIU's latest filing, from $214.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $283.5 million in Q4 2021 and bottomed at $221524.5 in Q3 2021.
• The 5-year median for Liabilities and Shareholders Equity is $209.5 million (2022), against an average of $188.3 million.
• The widest annual swing landed in 2021, when Liabilities and Shareholders Equity tumbled 99.92%; it then jumped 101044.55% in 2022.
• Tracing ACIU's Liabilities and Shareholders Equity over 5 years: stood at $283.5 million in 2021, then plunged by 31.93% to $193.0 million in 2022, then grew by 6.78% to $206.1 million in 2023, then climbed by 27.9% to $263.6 million in 2024, then decreased by 26.78% to $193.0 million in 2025.
• Per Business Quant, the three latest ACIU Liabilities and Shareholders Equity figures stand at $193.0 million (Q4 2025), $214.5 million (Q3 2025), and $229.8 million (Q2 2025).

Peer Comparison